Kynurenic Acid

Your body constantly breaks down tryptophan, an amino acid from the food you eat, and routes it down different chemical paths depending on what is happening inside you. One of those paths produces KYNA (kynurenic acid), a molecule that shows up in your urine and reflects how your immune system, brain, and metabolism are working together at a deeper level than standard labs reveal.

This is a research-grade marker, not a routine clinical test. But measuring it can give you an early window into pathways tied to depression, brain health, kidney function, and chronic inflammation, often before standard panels show anything is off.

What KYNA Actually Reflects

KYNA sits on one branch of what scientists call the kynurenine pathway, a chemical route your body uses to process tryptophan. When your immune system is activated, more tryptophan gets pushed down this pathway. The traffic then splits: one branch leads to KYNA, generally considered protective for brain cells, and another leads to quinolinic acid, which can be irritating to brain cells when it builds up.

Different cells favor different branches. Star-shaped support cells in your brain (called astrocytes) tend to produce KYNA, while immune cells like microglia and macrophages produce more quinolinic acid. The KYNA you see in your urine mostly reflects production outside the brain, since the molecule does not cross from the blood into brain tissue easily under normal conditions, though some studies suggest peripheral KYNA may penetrate the brain more readily during pathological states like cerebral ischemia.

The balance between these two branches matters more than either number alone. When the immune-activated branch dominates and KYNA falls behind, the chemistry tilts toward inflammation and excitability. When KYNA holds its share, the tilt is more protective. This is why the ratio of KYNA to other kynurenine metabolites often tells a richer story than KYNA on its own.

Depression and Diet

In a study of 169 healthy young adults, people eating more Western-style food (high in processed items, sugar, and saturated fat) had lower urinary KYNA. Lower KYNA, in turn, tracked with more depressive symptoms. The link held even after accounting for two common inflammation markers, suggesting KYNA is capturing something distinct from generic inflammation.

A separate metabolome study found that lower plasma kynurenic acid in people with depression predicted a better response to escitalopram, a common antidepressant. The pattern matters: this is not a number where higher is always better. It is a window into how diet, mood, and treatment response are connected through one chemical pathway. The relationship is complex, and other work has pointed to the kynurenine-to-tryptophan ratio, rather than KYNA alone, as the stronger predictor of escitalopram response.

Brain and Neurodegenerative Health

A large study of 914 people compared urine and serum metabolites across healthy controls, mild cognitive impairment, and Alzheimer's disease. Urinary KYNA and other tryptophan metabolites followed a gradient: highest in controls, lower in mild cognitive impairment, lowest in Alzheimer's. The ratio of kynurenine to tryptophan moved in the opposite direction, suggesting more tryptophan was being shunted into the pathway, but less of it was reaching the protective KYNA endpoint. Of note, the direction of change depends on the compartment measured: a 2025 meta-analysis found blood KYNA tends to be lower in Alzheimer's, while cerebrospinal fluid KYNA is actually higher, underscoring why compartment matters when reading this marker.

In early Parkinson's disease, urinary kynurenine (a metabolite directly upstream of KYNA) was higher than in controls. At an optimal cutoff, it correctly flagged roughly two-thirds of cases while correctly clearing most healthy people. Levels also tracked with disease stage and duration.

In autistic children, the chemistry tilted the other way: more tryptophan was converted to quinolinic and xanthurenic acids at the expense of KYNA. This shift toward the more excitable branch may relate to overlapping symptoms like seizures and sleep disturbance.

Kidney Function and Disease

Your kidneys clear KYNA from the blood, so urinary levels reflect both how much your body is producing and how well your kidneys are filtering and secreting it. In a study of 3,416 adults with chronic kidney disease, lower kidney clearance of KYNA-class molecules was strongly tied to faster disease progression and higher death rates, independent of standard kidney measures.

In a separate study of people with type 2 diabetes, higher plasma kynurenic acid associated with a slower decline in kidney function, while a high ratio of kynurenine to tryptophan, reflecting heavy traffic through the pathway, predicted faster decline. The evidence here is not all in one direction, though: a 2025 study from the CKD-REIN cohort found that higher serum kynurenic acid was associated with increased risk of kidney failure, the opposite of the diabetes finding. Note also that all of this evidence comes from blood measurements, not urine, so it should be read as related-but-not-identical context. The honest takeaway: KYNA's role in kidney disease appears bidirectional and depends on the population, the compartment measured, and how the pathway is being driven, so a single reading should be interpreted alongside kidney function and inflammation markers.

Reconciling the Counterintuitive Pattern

You will notice KYNA goes both ways across studies: lower in depression and Alzheimer's, mixed in kidney disease, mixed in COVID-19. The direction also depends heavily on the biological compartment measured: blood, urine, and cerebrospinal fluid can move in different directions for the same condition. This is not a simple high-bad or low-bad number. KYNA is a phenotype indicator, showing how the kynurenine pathway is being used in a given compartment. In conditions driven by inflammation crowding out the protective branch, you often see less KYNA. In conditions where the kidneys cannot clear it well, you may see more. Reading your result means looking at it alongside related markers and compartment context, not as a standalone verdict.

Inflammation and Infection

In hospitalized COVID-19 patients, urinary kynurenines climbed sharply, and the size of the rise tracked with disease severity and inflammatory markers like C-reactive protein. In one cohort, urinary kynurenine and the kynurenine-to-tryptophan ratio predicted the need for oxygen therapy or in-hospital death. Across cohorts, urine kynurenines reflected how hard the immune system was working and how much tryptophan was being diverted into the pathway.

Gut, Pain, and Other Conditions

In small intestinal bacterial overgrowth with depression, urinary kynurenine and quinolinic acid rose, the KYNA-to-kynurenine ratio fell, and treating the gut overgrowth with rifaximin improved both the kynurenine profile and mental symptoms. In constipation-predominant irritable bowel syndrome, higher urinary kynurenine, quinolinic acid, and KYNA correlated with the severity of depression.

Among 169 active-duty service members with chronic pain, a composite urine metabolite indicator that includes kynurenic acid correlated with fatigue, anxiety, depression, physical function, and how much pain interfered with daily life. KYNA showed some of the strongest individual associations among the metabolites tested.

In episodic migraine, urinary KYNA was lower, while kynurenine and quinolinic acid were higher. Altered ratios distinguished migraine patients from controls and related to migraine burden, hinting at a shift toward the more excitable branch of the pathway.

Why One Reading Is Not Enough

KYNA is a dynamic marker. It shifts with what you eat, whether you are sick, how your kidneys are working, and how active your immune system is on a given day. In a small study of an 8-day fast, urinary kynurenines rose substantially, and serum and urine did not always move in the same direction. A single reading captures one moment in a moving system.

This is why a baseline plus follow-up testing is far more useful than any one number. Get a first measurement, then retest in 3 to 6 months if you are making meaningful changes (diet, an intervention for inflammation, treatment for an underlying condition), and at least annually after that to watch your trend. Because there are no standardized clinical cutpoints for urinary KYNA yet, your personal trajectory and its companion markers carry more weight than the absolute value.

When Results Can Be Misleading

Several factors can distort a single urinary KYNA reading without reflecting your real underlying biology:

• Recent illness or infection: acute immune activation pushes more tryptophan into the kynurenine pathway, which can shift KYNA in either direction depending on the disease.
• Kidney function: because KYNA is cleared by the kidneys, reduced filtration or secretion can change urine levels independently of how much your body is producing.
• Fasting and major dietary shifts: prolonged fasting raises kynurenines, and serum and urine levels do not always move together.
• Medication interactions: stimulants like methylphenidate have been shown to modestly change urinary KYNA in children with ADHD, though the effect is small.

Decision Pathway for Out-of-Pattern Results

If your urinary KYNA is unexpectedly low or high, the next step is not to act on the number alone. Pair the result with companion tests that give context. Consider kidney function markers (creatinine, cystatin C, eGFR) to rule out filtration issues distorting the reading. Add inflammation markers (hs-CRP, the high-sensitivity C-reactive protein test) to see whether systemic inflammation is driving the kynurenine pathway harder. Tryptophan and other kynurenine pathway metabolites give you the ratios that often matter more than KYNA alone.

If your pattern suggests heavy pathway flux alongside cognitive symptoms, mood changes, or chronic gut issues, that combination warrants a conversation with a clinician who works with metabolomic data, often a functional medicine physician, integrative neurologist, or nephrologist depending on which other markers are off. A single low KYNA in an otherwise healthy person with no symptoms is mostly a signal to keep tracking. A low KYNA paired with depressive symptoms and a high kynurenine-to-tryptophan ratio is a stronger nudge to investigate inflammation, diet, and gut health.